Citius Oncology Files 8-K Report
Ticker: CTOR · Form: 8-K · Filed: Sep 5, 2024 · CIK: 1851484
| Field | Detail |
|---|---|
| Company | Citius Oncology, INC. (CTOR) |
| Form Type | 8-K |
| Filed Date | Sep 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, company-update
TL;DR
Citius Oncology filed an 8-K. Check for updates on financials/events.
AI Summary
On September 5, 2024, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events. No specific financial figures or new material events were detailed in the provided text excerpt.
Why It Matters
This filing signals that Citius Oncology is providing updated information to the SEC, which could include material events or financial disclosures relevant to investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific material events or financial data that would indicate a change in risk.
Key Players & Entities
- CITIUS ONCOLOGY, INC. (company) — Registrant
- 0001851484 (company) — Central Index Key
- TenX Keane Acquisition (company) — Former Company Name
- September 5, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing for Citius Oncology, Inc.?
The filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, primarily covering 'Other Events' and 'Financial Statements and Exhibits'.
When was this 8-K report filed?
The report was filed on September 5, 2024.
What is Citius Oncology, Inc.'s principal executive office address?
The principal executive offices are located at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.
What was Citius Oncology, Inc.'s former company name?
The company was formerly known as TenX Keane Acquisition.
What is Citius Oncology, Inc.'s IRS Employer Identification Number?
The IRS Employer Identification Number is 99-4362660.
Filing Stats: 420 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2024-09-05 16:15:59
Filing Documents
- ea0213635-8k_citius.htm (8-K) — 27KB
- ea021363501ex99-1_citius.htm (EX-99.1) — 34KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-076111.txt ( ) — 248KB
- ctor-20240905.xsd (EX-101.SCH) — 3KB
- ctor-20240905_lab.xml (EX-101.LAB) — 33KB
- ctor-20240905_pre.xml (EX-101.PRE) — 22KB
- ea0213635-8k_citius_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On September 5, 2024, Citius Oncology, Inc. issued a press release to announce that LYMPHIR has been added to the NCCN Clinical Practice Guidelines in Oncology. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . The following exhibit is filed herewith: Exhibit No. Description 99.1 Press Release dated September 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS ONCOLOGY, INC. Date: September 5, 2024 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer 2